HUE041598T2 - Újfajta citosztatikus 7-deazapurin nukleozidok - Google Patents

Újfajta citosztatikus 7-deazapurin nukleozidok

Info

Publication number
HUE041598T2
HUE041598T2 HUE16174985A HUE16174985A HUE041598T2 HU E041598 T2 HUE041598 T2 HU E041598T2 HU E16174985 A HUE16174985 A HU E16174985A HU E16174985 A HUE16174985 A HU E16174985A HU E041598 T2 HUE041598 T2 HU E041598T2
Authority
HU
Hungary
Prior art keywords
deazapurine nucleosides
new cytostatic
cytostatic
new
deazapurine
Prior art date
Application number
HUE16174985A
Other languages
English (en)
Hungarian (hu)
Inventor
Michal Hocek
Petr Naus
Original Assignee
Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic filed Critical Inst Of Organic Chemistry And Biochemistry Of The Academy Of Sciences Of The Czech Republic
Publication of HUE041598T2 publication Critical patent/HUE041598T2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/14—Pyrrolo-pyrimidine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/40—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data
    • H02J7/44—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries characterised by the exchange of charge or discharge related data between battery management systems and power sources
    • H—ELECTRICITY
    • H02—GENERATION; CONVERSION OR DISTRIBUTION OF ELECTRIC POWER
    • H02J—ELECTRIC POWER NETWORKS; CIRCUIT ARRANGEMENTS OR SYSTEMS FOR SUPPLYING OR DISTRIBUTING ELECTRIC POWER; SYSTEMS FOR STORING ELECTRIC ENERGY
    • H02J7/00—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries
    • H02J7/485—Circuit arrangements for charging or discharging batteries or for supplying loads from batteries with provisions for charging different types of batteries

Landscapes

  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Power Engineering (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
HUE16174985A 2008-01-18 2009-01-15 Újfajta citosztatikus 7-deazapurin nukleozidok HUE041598T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US2224708P 2008-01-18 2008-01-18

Publications (1)

Publication Number Publication Date
HUE041598T2 true HUE041598T2 (hu) 2019-05-28

Family

ID=40434932

Family Applications (2)

Application Number Title Priority Date Filing Date
HUE16174985A HUE041598T2 (hu) 2008-01-18 2009-01-15 Újfajta citosztatikus 7-deazapurin nukleozidok
HUE09702842A HUE030767T2 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Family Applications After (1)

Application Number Title Priority Date Filing Date
HUE09702842A HUE030767T2 (en) 2008-01-18 2009-01-15 Novel cytostatic 7-deazapurine nucleosides

Country Status (18)

Country Link
US (1) US8093226B2 (https=)
EP (2) EP3133080B1 (https=)
JP (2) JP5485172B2 (https=)
CN (1) CN101977923B (https=)
AU (1) AU2009204568B2 (https=)
CA (1) CA2711384C (https=)
CY (2) CY1118104T1 (https=)
DK (2) DK2231689T3 (https=)
ES (2) ES2693551T3 (https=)
HR (2) HRP20161344T1 (https=)
HU (2) HUE041598T2 (https=)
LT (2) LT2231689T (https=)
NZ (1) NZ586610A (https=)
PL (2) PL2231689T3 (https=)
PT (2) PT2231689T (https=)
SI (2) SI3133080T1 (https=)
TR (1) TR201815961T4 (https=)
WO (1) WO2009089804A1 (https=)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202003901UA (en) 2005-12-13 2020-05-28 Incyte Holdings Corp Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors
KR20150036210A (ko) 2007-06-13 2015-04-07 인사이트 코포레이션 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
PT2421879E (pt) * 2009-04-22 2013-12-09 Acad Of Science Czech Republic Novos 7-deazapurina nucleósidos para utilizações terapêuticas
AR076794A1 (es) 2009-05-22 2011-07-06 Incyte Corp Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen
SI2432472T1 (sl) * 2009-05-22 2019-11-29 Incyte Holdings Corp 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK
TW201113285A (en) 2009-09-01 2011-04-16 Incyte Corp Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors
EP3354652B1 (en) 2010-03-10 2020-05-06 Incyte Holdings Corporation Piperidin-4-yl azetidine derivatives as jak1 inhibitors
PE20130216A1 (es) 2010-05-21 2013-02-27 Incyte Corp Formulacion topica para un inhibidor de jak
KR101817221B1 (ko) * 2010-11-18 2018-01-10 카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 치환된 4-(셀레노펜-2(또는 3)-일아미노)피리미딘 화합물 및 이의 사용방법
PE20140146A1 (es) 2010-11-19 2014-02-06 Incyte Corp Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak
US9034884B2 (en) 2010-11-19 2015-05-19 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors
CN103797010B (zh) 2011-06-20 2016-02-24 因塞特控股公司 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物
TW201313721A (zh) 2011-08-18 2013-04-01 Incyte Corp 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物
UA111854C2 (uk) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн Способи і проміжні сполуки для отримання інгібіторів jak
TW201406761A (zh) 2012-05-18 2014-02-16 Incyte Corp 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物
PH12020551186B1 (en) 2012-11-15 2024-03-20 Incyte Holdings Corp Sustained-release dosage forms of ruxolitinib
RS62867B1 (sr) 2013-03-06 2022-02-28 Incyte Holdings Corp Postupci i intermedijeri za dobijanje inhibitora jak
SMT202000315T1 (it) 2013-08-07 2020-07-08 Incyte Corp Forme di dosaggio a rilascio prolungato per un inibitore di jak1
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
CA3029170C (en) 2016-06-29 2021-02-16 Ustav Organicke Chemie A Biochemie Av Cr, V.V.I. Substituted thienopyrrolopyrimidine ribonucleosides for therapeutic use
CZ307334B6 (cs) 2016-08-02 2018-06-13 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v.v.i. Substituované heteropentadieno-pyrrolopyrimidinové ribonukleosidy pro terapeutické použití
WO2019113487A1 (en) 2017-12-08 2019-06-13 Incyte Corporation Low dose combination therapy for treatment of myeloproliferative neoplasms
SG11202007164UA (en) 2018-01-30 2020-08-28 Incyte Corp Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one)
CZ308104B6 (cs) 2018-03-12 2020-01-08 Ăšstav organickĂ© chemie a biochemie AV ÄŚR, v. v. i. Pyridinopyrrolopyrimidinové ribonukleosidy pro terapeutické použití
SMT202400306T1 (it) 2018-03-30 2024-09-16 Incyte Corp Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak.
WO2020206289A1 (en) * 2019-04-05 2020-10-08 Prelude Therapeutics, Incorporated Selective inhibitors of protein arginine methyltransferase 5
CN114008064A (zh) * 2019-06-18 2022-02-01 大鹏药品工业株式会社 具有吡咯并嘧啶骨架的新型的磷酸酯化合物或其药学上可接受的盐
CN115515593A (zh) * 2020-02-17 2022-12-23 勒芬天主教大学 作为药物的新的6-取代的7-脱氮嘌呤和相应的核苷
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
CN112190590A (zh) * 2020-11-06 2021-01-08 牡丹江医学院 一种治疗动脉粥样硬化的硒核苷及其药物组合物

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS50125033A (https=) * 1974-03-19 1975-10-01
IL108523A0 (en) 1993-02-03 1994-05-30 Gensia Inc Pharmaceutical compositions containing adenosine kinase inhibitors for preventing or treating conditions involving inflammatory responses and pain
JPH10158293A (ja) * 1996-08-08 1998-06-16 Rikagaku Kenkyusho ３’−デオキシリボヌクレオチド誘導体
JP3489991B2 (ja) * 1997-07-07 2004-01-26 理化学研究所 ３’−デオキシリボヌクレオチド誘導体
JP3318579B2 (ja) * 1997-07-07 2002-08-26 理化学研究所 Ｄｎａの塩基配列決定方法
CZ9901996A3 (cs) * 1999-06-04 2001-01-17 Ústav organické chemie a biochemie AV ČR Nové 6-fenylpurinové 9-ß-D-ribonukleosidy s antineoplastickým účinkem, jejich použití k přípravě farmaceutických preparátů a farmaceutické přípravky, které je obsahují
WO2003051899A1 (en) * 2001-12-17 2003-06-26 Ribapharm Inc. Deazapurine nucleoside libraries and compounds
NZ546055A (en) * 2003-08-27 2010-05-28 Biota Scient Management Novel tricyclic nucleosides or nucleotides as therapeutic agents
CN101043893A (zh) * 2004-10-21 2007-09-26 默克公司 治疗RNA－依赖性RNA病毒感染的氟化吡咯并[2,3－d]嘧啶核苷
EP1804812A4 (en) * 2004-10-21 2009-09-02 Merck & Co Inc FLUORINATED PYRROLO [2,3-D] PYRIMIDIN NUCLEOSIDES FOR THE TREATMENT OF RNA-DEPENDENT RNA VIRUS INFECTIONS
US7405204B2 (en) * 2005-04-25 2008-07-29 Genelabs Technologies, Inc. Nucleoside compounds for treating viral infections

Also Published As

Publication number Publication date
JP2011509949A (ja) 2011-03-31
HUE030767T2 (en) 2017-05-29
CN101977923B (zh) 2014-10-08
CN101977923A (zh) 2011-02-16
EP2231689B1 (en) 2016-07-20
DK3133080T3 (en) 2018-11-26
HRP20181774T1 (hr) 2018-12-28
HRP20161344T1 (hr) 2016-11-18
SI2231689T1 (sl) 2016-11-30
ES2598503T3 (es) 2017-01-27
PL2231689T3 (pl) 2017-01-31
TR201815961T4 (tr) 2018-11-21
EP3133080A1 (en) 2017-02-22
NZ586610A (en) 2012-08-31
AU2009204568B2 (en) 2013-10-03
SI3133080T1 (sl) 2018-12-31
LT3133080T (lt) 2018-11-12
LT2231689T (lt) 2016-10-25
ES2693551T3 (es) 2018-12-12
DK2231689T3 (en) 2016-09-19
PL3133080T3 (pl) 2018-12-31
AU2009204568A1 (en) 2009-07-23
JP5485172B2 (ja) 2014-05-07
US8093226B2 (en) 2012-01-10
CA2711384A1 (en) 2009-07-23
EP3133080B1 (en) 2018-08-01
JP2014058567A (ja) 2014-04-03
CY1118104T1 (el) 2017-06-28
PT3133080T (pt) 2018-11-16
WO2009089804A1 (en) 2009-07-23
CA2711384C (en) 2016-07-26
US20090203637A1 (en) 2009-08-13
CY1121364T1 (el) 2020-05-29
EP2231689A1 (en) 2010-09-29
PT2231689T (pt) 2016-10-07

Similar Documents

Publication Publication Date Title
PL3133080T3 (pl) Nowe cytostatyczne nukleozydy 7-deazapurynowe
BRPI0922508A2 (pt) Análogos de nucleosídeo
DK2356129T3 (da) Substituerede alpha-L-bicykliske nukleosider
BRPI0819797A2 (pt) compostos de nucleosídeos antivirais
BRPI0907435A2 (pt) Derivados de 5-flúor pirimidina
BRPI0813707A2 (pt) Derivados de pirimidinil-piridazinona
BRPI0820112A2 (pt) Derivados de isoxazol-piridina
BRPI0809992A2 (pt) Derivados de pirrolopirimidina
BRPI0820113A2 (pt) Derivados de isoxazolo-piridazina
DK2308877T3 (da) Imidazopyridin-2-on-derivater
BRPI0916233A2 (pt) compostos heterocíclicos antivirais
BRPI0812155A2 (pt) derivados de espiroindolinona
BRPI0817935A2 (pt) Derivados de biarila
BRPI0915064A2 (pt) derivados de qunoxalinadiona
DK2511282T3 (da) Uracylspirooxetannukleosider
BRPI0913832A2 (pt) derivados de pirrolopiridinilpirimidin-2-ilamina
BRPI0814236A2 (pt) Derivados de quinazolinamida
BRPI0812518A2 (pt) Derivados de indazolamida
BRPI0820649A2 (pt) Derivados de isoxazalo-pirazina
BRPI0910534A2 (pt) terapia antiviral
DK2275414T3 (da) Cyclopentylacrylamidderivat
BRPI0920496A2 (pt) derivados substituídos de pirimidina etriazina
BRPI0924121A2 (pt) compostos antivirais heterocíclicos
ATE545635T1 (de) Substituierte n-oxidpyrazinderivate
BRPI0913234A2 (pt) derivados de tiazolilpiperidina